Compare AURA & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AURA | SLBT |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.5M | 942.1M |
| IPO Year | 2021 | 2025 |
| Metric | AURA | SLBT |
|---|---|---|
| Price | $6.09 | $1.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.60 | N/A |
| AVG Volume (30 Days) | ★ 648.1K | 108.5K |
| Earning Date | 11-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $1.42 |
| 52 Week High | $9.54 | $6.25 |
| Indicator | AURA | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 35.86 |
| Support Level | $6.05 | N/A |
| Resistance Level | $6.27 | $3.36 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 24.38 | 32.89 |
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.